Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

Nizar M. Tannir; Thomas Powles; Bernard Escudier; Frede Donskov; Viktor Gruenwald; Cora N. Sternberg; Manuela Schmidinger; Patrick Schoeffski; Cezary Szczylik; Katriina Peltola; Dmitry Nosov; Bohuslav Melichar; Douglas Clary; Christian Scheffold; Robert J. Motzer; Toni K. Choueiri

doi:10.3233/KCA-190080

Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

Nizar M. Tannir, Thomas Powles, Bernard Escudier, Frede Donskov, Viktor Gruenwald, Cora N. Sternberg, Manuela Schmidinger, Patrick Schoeffski, Cezary Szczylik, Katriina Peltola, Dmitry Nosov, Bohuslav Melichar, Douglas Clary, Christian Scheffold, Robert J. Motzer, Toni K. Choueiri

Tutkimustuotos: Artikkelijulkaisu › Artikkeli › Tieteellinen › vertaisarvioitu

Alkuperäiskieli	englanti
Lehti	Kidney cancer
Vuosikerta	4
Numero	1
Sivut	29-39
Sivumäärä	11
ISSN	2468-4562
DOI - pysyväislinkit	https://doi.org/10.3233/KCA-190080
Tila	Julkaistu - 2020
OKM-julkaisutyyppi	A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä, vertaisarvioitu

Tieteenalat

3122 Syöpätaudit

Pääsy asiakirjaan

10.3233/KCA-190080

kca_2020_4-1_kca-4-1-kca190080_kca-4-kca190080Lopullinen julkaistu versio, 392 KBLisenssi: CC BY-NC

Siteeraa tätä

Tannir, N. M., Powles, T., Escudier, B., Donskov, F., Gruenwald, V., Sternberg, C. N., Schmidinger, M., Schoeffski, P., Szczylik, C., Peltola, K., Nosov, D., Melichar, B., Clary, D., Scheffold, C., Motzer, R. J., & Choueiri, T. K. (2020). Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma. Kidney cancer, 4(1), 29-39. https://doi.org/10.3233/KCA-190080

@article{68d06f7f4b824e0f8499893165000e0a,

title = "Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma",

keywords = "Nephrectomy, renal cell carcinoma, cabozantinib, everolimus, ENDOTHELIAL GROWTH-FACTOR, CYTOREDUCTIVE NEPHRECTOMY, TARGETED THERAPY, INTERFERON-ALPHA, 2ND-LINE TREATMENT, OPEN-LABEL, SURVIVAL, SUNITINIB, EFFICACY, AXITINIB, 3122 Cancers",

author = "Tannir, {Nizar M.} and Thomas Powles and Bernard Escudier and Frede Donskov and Viktor Gruenwald and Sternberg, {Cora N.} and Manuela Schmidinger and Patrick Schoeffski and Cezary Szczylik and Katriina Peltola and Dmitry Nosov and Bohuslav Melichar and Douglas Clary and Christian Scheffold and Motzer, {Robert J.} and Choueiri, {Toni K.}",

year = "2020",

doi = "10.3233/KCA-190080",

language = "English",

volume = "4",

pages = "29--39",

journal = "Kidney cancer",

issn = "2468-4562",

publisher = "IOS PRESS",

number = "1",

}

Tannir, NM, Powles, T, Escudier, B, Donskov, F, Gruenwald, V, Sternberg, CN, Schmidinger, M, Schoeffski, P, Szczylik, C, Peltola, K, Nosov, D, Melichar, B, Clary, D, Scheffold, C, Motzer, RJ & Choueiri, TK 2020, 'Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma', Kidney cancer, Vuosikerta 4, Nro 1, Sivut 29-39. https://doi.org/10.3233/KCA-190080

TY - JOUR

T1 - Clinical Outcomes by Nephrectomy Status In METEOR, A Randomized Phase 3 Trial of Cabozantinib Versus Everolimus in Patients with Advanced Renal Cell Carcinoma

AU - Tannir, Nizar M.

AU - Powles, Thomas

AU - Escudier, Bernard

AU - Donskov, Frede

AU - Gruenwald, Viktor

AU - Sternberg, Cora N.

AU - Schmidinger, Manuela

AU - Schoeffski, Patrick

AU - Szczylik, Cezary

AU - Peltola, Katriina

AU - Nosov, Dmitry

AU - Melichar, Bohuslav

AU - Clary, Douglas

AU - Scheffold, Christian

AU - Motzer, Robert J.

AU - Choueiri, Toni K.

PY - 2020

Y1 - 2020

KW - Nephrectomy

KW - renal cell carcinoma

KW - cabozantinib

KW - everolimus

KW - ENDOTHELIAL GROWTH-FACTOR

KW - CYTOREDUCTIVE NEPHRECTOMY

KW - TARGETED THERAPY

KW - INTERFERON-ALPHA

KW - 2ND-LINE TREATMENT

KW - OPEN-LABEL

KW - SURVIVAL

KW - SUNITINIB

KW - EFFICACY

KW - AXITINIB

KW - 3122 Cancers

U2 - 10.3233/KCA-190080

DO - 10.3233/KCA-190080

M3 - Article

VL - 4

SP - 29

EP - 39

JO - Kidney cancer

JF - Kidney cancer

SN - 2468-4562

IS - 1

ER -